<DOC>
	<DOCNO>NCT00005018</DOCNO>
	<brief_summary>The purpose study see safe effective give HIV-positive patient combination anti-HIV drug ( abacavir [ ABC ] plus efavirenz [ EFV ] plus didanosine [ ddI ] ) without hydroxyurea ( HU ) .</brief_summary>
	<brief_title>Safety Effectiveness Combination Anti-HIV Drug Treatment</brief_title>
	<detailed_description>Patients randomize one two treatment arm : ABC/EFV/ddI ABC/EFV/ddI/HU . In second treatment arm , patient randomize receive HU begin Baseline , ABC/EFV/ddI start , Week 8 . Delaying HU may help offset cytopenic effect HU , reflect blunted CD4 cell response . Patients stratify accord screen plasma HIV-1 RNA level ( 400 10,000 copies/ml 10,000 100,000 copies/ml ) . Participants study receive study-related exam , lab test , study medication cost 48-week treatment period . The safety effectiveness non-protease inhibitor rescue therapy evaluate routinely measure viral load CD4 cell count , well side effect cause medication . All medication approve FDA consider investigational .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are take lamivudine ( 3TC ) plus either zidovudine ( ZDV ) stavudine ( d4T ) . Patients may also take one two protease inhibitor ( PIs ) . ( Patients qualify drug substitution make drug stop 2 month certain condition . ) Have viral load 400 copies/ml ( treatment failure ) 16 week treatment . Have viral load 400 100,000 copies/ml . Have CD4 cell count 100 cells/mm3 . Have consent parent guardian ( 18 ) . Agree use barrier form birth control ( condom ) study . Are least 13 year old . Exclusion Criteria Patients eligible study : Are unable take medication mouth . Have certain opportunistic ( AIDSrelated ) infection disease . Have certain serious medical condition diabetes disease liver , pancreas , heart . Have history lymphoma . Have peripheral neuropathy ( painful condition affect nervous system ) within 2 month study entry . Have take antiHIV drug 1.5 year without effect HIV level . Have ever take ABC , ddI , type antiHIV drug call NNRTI ( EFV ) . Are unable complete 48 week study take study drug . Are receive certain investigational treatment . Are receive radiation therapy chemotherapy within 8 week study entry , plan receive one treatment study . ( Local treatment Kaposi 's sarcoma allow . ) Are take certain medication include might affect immune system HIV level . Have receive vaccine within 8 week study entry HIV vaccine within 3 month study entry . Are pregnant breastfeeding . Abuse alcohol drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
	<keyword>efavirenz</keyword>
</DOC>